Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.05 USD
Change Today -0.02 / -0.97%
Volume 16.7K
ALXA On Other Exchanges
As of 8:10 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

alexza pharmaceuticals inc (ALXA) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/16/14 - $5.27
52 Week Low
12/17/14 - $1.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

alexza pharmaceuticals inc (ALXA) Related Businessweek News

No Related Businessweek News Found

alexza pharmaceuticals inc (ALXA) Details

Alexza Pharmaceuticals, Inc., a pharmaceutical company, focuses on the research, development, and commercialization of proprietary products for the acute treatment of central nervous system conditions worldwide. The company’s product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. It offers ADASUVE (Staccato loxapine) inhalation powder for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. The company also engages in developing AZ-002 (Staccato alprazolam) for treating patients with acute repetitive seizures, as well as in Phase 2a study for patients with epilepsy; and AZ-007 (Staccato zaleplon) for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep. It has collaboration agreement with Grupo Ferrer Internacional S.A. The company was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005.Alexza Pharmaceuticals, Inc. was incorporated in 2000 and is based in Mountain View, California.

81 Employees
Last Reported Date: 03/13/15
Founded in 2000

alexza pharmaceuticals inc (ALXA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $526.0K
Compensation as of Fiscal Year 2013.

alexza pharmaceuticals inc (ALXA) Key Developments

Alexza Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt

Alexza Pharmaceuticals Inc. filed its 10-K on Mar 13, 2015 for the period ending Dec 31, 2014. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Alexza Pharmaceuticals Inc. Reports Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014

Alexza Pharmaceuticals Inc. reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014. The net loss for the fourth quarter was $6.7 million compared to $5.7 million during the same quarter in 2013. Revenue was $1,454,000 compared to $1,309,000 a year ago. Loss from operations was $7,264,000 compared to $9,357,000 a year ago. Basic and diluted loss per share was $0.35 compared to $0.33 a year ago. The net loss for the years ended December 31, 2014 and 2013 was $36.7 million and $39.6 million, respectively. Revenue was $5,561,000 compared to $47,839,000 a year ago. Loss from operations was $37,456,000 compared to income from operations of $1,770,000 a year ago. Basic and diluted loss per share was $2.07 compared to $2.38 a year ago.

Alexza Pharmaceuticals Inc. to Report Q4, 2014 Results on Mar 09, 2015

Alexza Pharmaceuticals Inc. announced that they will report Q4, 2014 results at 5:00 PM, US Eastern Standard Time on Mar 09, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXA:US $2.05 USD -0.02

ALXA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALXA.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALXA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXZA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at